



**UNITED STATES
NUCLEAR REGULATORY COMMISSION**
REGION I
2100 RENAISSANCE BOULEVARD, SUITE 100
KING OF PRUSSIA, PA 19406-2713

December 29, 2015

Docket No. 03032974
Control No. 589353

License No. 45-25221-01MD

Kenneth L. Smithmier
President and CEO
Illinois Health and Science
P.O. Box 3367
Decatur, IL 62524

SUBJECT: IBA MOLECULAR NORTH AMERICA, INC.'S WEST VIRGINIA AND MISSOURI SITES, NOTIFICATION OF CORPORATE OVERSIGHT CHANGES, CONTROL NO. 589353

Dear Mr. Smithmier:

This is in reference to your letter dated October 30, 2015 notifying the NRC that you have permitted Mr. Todd Hockemeyer authority to oversee quality and regulatory affairs for IBA Molecular North America, Inc., under NRC License No. 45-25221-01MD. Thank you for the information.

In our letter dated July 15, 2015, NRC documented our understanding of the indirect license transfer of NRC Materials License Nos. 45-25221-01MD and 45-25221-05 as described in your letter dated May 6, 2015. In your letter you described the transfer resulting from a sale between Rose and C-Molecular, Inc. At that time, we understood that these transfers did not result in any changes to the licensee name, licensed materials, persons using the licensed material, location of use, or persons responsible for the radiation safety program. In our letter dated July 15, 2015, we also noted that any future changes require submission of a request to amend the license. It appears that additional changes have occurred in the Corporate Radiation Safety Program oversight and include involvement by personnel working for a company named Zevacor. In accordance with 10 CFR 30.34(b)(1), please submit an amendment describing all parties involved in regulatory oversight for IBA Molecular North America, Inc. operating under License Nos. 45-25221-01MD and 45-25221-05 and any changes to the Radiation Safety Program that have occurred since your May 6, 2015 letter. In particular describe: (i) any changes in personnel or duties that relate to the licensed program; (ii) training and experience for any new personnel involved in the program; and (iii) any changes in the organization, location, facilities, equipment or procedures that relate to the licensed program. In addition, in the submission signed by you, please confirm that Mr. Hockemeyer may make regulatory commitments for licensing on behalf of senior management at Illinois Health & Science for IBA Molecular North America, Inc.

K. Smithmier

2

Your cooperation is appreciated.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

cc:

Michael A. Levy, R.Ph., Radiation Safety Officer, IBA Molecular North America, Inc.
Todd Hockemeyer, V.P. Quality & Regulatory Affairs, IBA Molecular North America, Inc.

DOCUMENT NAME: G:\WordDocs\Current\Lic Cvr Letter\L45-25221-01MD.589353.docx

SUNSI Review Complete: PLanzisera

After declaring this document an Official Agency Record it **will** be released to the Public.

To receive a copy of this document, indicate in the box: AC = Copy w/o attach/encl AE = Copy w/ attach/encl AN = No copy

OFFICE	DNMS/RI	N	DNMS/RI	DNMS/RI			
NAME	PLanzisera/PL						
DATE	12-29-15						

OFFICIAL RECORD COPY